No profile data available.
Phathom Pharmaceuticals, Inc. (PHAT) is a healthcare company in the digestive system treatment drugs industry, based in Florham Park, United States, with about 371 full-time employees.
It reported revenue of $55.25 million for fiscal year 2024, up 8001.5% from fiscal year 2023, and net income of -$334.33 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $49.50 million, up 202.7% from a year before. Its market capitalization was $586.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Phathom Pharmaceuticals reported $55.25 million in revenue for fiscal year 2024, up 8001.5% from $682,000 in fiscal year 2023. In Q3 2025 revenue was $49.50 million.
$586.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Spyre Therapeutics, Inc. (SYRE), Abivax Société Anonyme (ABVX), Ironwood Pharmaceuticals, Inc. (IRWD), Palisade Bio, Inc. (PALI).